Advanced search
Publication Cover
Colorectal Cancer Volume 11, 2022 - Issue 1
Submit an article Journal homepage
884
Views
0
CrossRef citations to date
0
Altmetric
Short Communication

Phase IIIb study of the bevacizumab biosimilar candidate BI 695502 plus mFOLFOX6 in metastatic colorectal cancer

Tanios S Bekaii-Saab1 Mayo Clinic Cancer Center, Department of Internal Medicine, Mayo Clinic Hospital, 5777E. Mayo Blvd, Phoenix, AZ85054, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-7721-1699View further author information
ORCID Icon,
Sigrid Balser2 Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Str. 65, 88400Biberach an der Riss, GermanyView further author information
,
Ragna Lohmann3 Boehringer Ingelheim International GmbH, Binger Str. 173, 55218Ingelheim am Rhein, GermanyView further author information
,
Hasan Daoud3 Boehringer Ingelheim International GmbH, Binger Str. 173, 55218Ingelheim am Rhein, GermanyView further author information
,
Bernd Liedert4 (Formerly at) Boehringer Ingelheim International GmbH, Binger Str. 173, 55218Ingelheim am Rhein, GermanyView further author information
&
Dorothee Schliephake3 Boehringer Ingelheim International GmbH, Binger Str. 173, 55218Ingelheim am Rhein, GermanyView further author information
Article: CRC38 | Received 03 Mar 2022, Accepted 11 Oct 2022, Published online: 09 Nov 2022

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.